Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, and Pharmacokinetic Profile of ANB020 Administered to Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Etokimab (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms ATLAS
- Sponsors AnaptysBio
- 08 Nov 2019 According to an AnaptysBio media release, The Company will be receiving additional data and plans to provide a detailed update in the first quarter of 2020.
- 08 Nov 2019 Primary endpoint has not been met. (Percent change in Eczema Area and Severity Index (EASI))
- 07 Aug 2018 According to an AnaptysBio media release, data from this study is expected in second half of 2019.